Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.

Manuel R Espinoza-Gutarra¹, Brooke Jarret², Xiaoliang Wang², Anosheh Afghahi^2,3, Sejong Bae^4,5

¹The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, USA.

²Flatiron Health, New York, New York, USA.

³University of Colorado School of Medicine, Aurora, Colorado, USA.

⁴Wellstar MCG Health Medical Center, Augusta, Georgia, USA.

⁵Augusta University Georgia Cancer Center, Augusta, Georgia, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND AND AIMS: Acute myeloid leukemia (AML) remains the most common cause of death in adults with acute leukemia. Tyrosine kinase inhibitors (TKIs) have shown significant clinical efficacy in defined patient subgroups. Real-world outcomes of AML patients undergoing TKI therapy have not been widely reported. METHODS: In this real-world retrospective study, we included 482 adult patients with…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.